The Quantellect read.As of Nov 19, 2026, 4 active firms cover Protara Therapeutics Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $24.00 to $28.00, so the covering firms are broadly aligned. The average target of $26.25 sits 1022% above the current $2.34. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.44 next quarter toward $-1.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$26.25
+1021.8% upside
Average target across 4 active firms as of Nov 19, 2026 vs $2.34 current
Highest Target$28.00
Average Target$26.25
Lowest Target$24.00
Detailed analyst forecasts for TARA
Showing 1–5 of 5 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate TARA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TARA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.44
Range $-0.46 – $-0.42 · 2 analysts · +42% YoY
Next period, 2 analysts expect Protara Therapeutics Inc to earn $-0.44 a share (range $-0.46 – $-0.42), versus $-0.31 a year earlier. Full-year consensus is $-1.48, growing to $-1.77 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $1.0M next year.
Top analysts covering Protara Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TARA.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$20.00+754.7% to target
Overall win rate
53%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$27.00+1053.8% to target
Overall win rate
45%
+ Follow
#3
Brian Cheng
JP Morgan · Rank #87
Buy
$26.00+1011.1% to target
Overall win rate
51%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$23.00+882.9% to target
Overall win rate
39%
+ Follow
#5
George Farmer
Scotiabank · Rank #311
Buy
$12.00+412.8% to target
Overall win rate
44%
+ Follow
TARA stock forecast FAQ
What is TARA's average 12-month price target?+
The 4 active firms with a live target average $26.25 for Protara Therapeutics Inc over the next 12 months, ranging from a $28.00 high to a $24.00 low, as of Nov 19, 2026.
Is TARA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TARA?+
The Street-high target is $28.00 (Oppenheimer), and the Street-low is $24.00 (Piper Sandler). The average of all 4 active-firm targets is $26.25.
How many active Wall Street firms cover TARA?+
4 active firms have a recognized rating on Protara Therapeutics Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TARA?+
Among analysts who currently cover TARA, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $20.00 target.
What is Protara Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.44 per share (range $-0.46 – $-0.42) across 2 analysts. Full-year EPS is projected at $-1.48, rising to $-1.77 the following year.
How much revenue is Protara Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $1.0M next year.
Have analysts been upgrading or downgrading TARA lately?+
As of Nov 19, 2026, 4 of 4 active firms rate TARA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TARA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.